The naive question: if a drug that mimics one gut hormone already helps people lose weight, why build one that mimics two or three? Because the body doesn't regulate metabolism with a single switch — it uses a panel of them, and pushing several at once turns out to work better than pushing one hard.
Think of it like adjusting a room's comfort with one dial versus three. GLP-1 alone is the temperature dial. Add GIP and you're also controlling humidity; add glucagon and you're managing airflow. Each hormone receptor is a separate control, and the 2022 filings are full of single molecules wired to turn several at once.
Hanmi Pharmaceutical's grant US11332508B2 is a clean example: a triple glucagon/GLP-1/GIP receptor agonist — one peptide, three targets. The design isn't subtle; it is right there in the title.
Others took the two-button approach. Zealand Pharma's US11395847B2 covers acylated GLP-1/GLP-2 dual agonists, pairing GLP-1 with a different partner hormone. And publication US20220098265A1 describes glucagon/GLP-1 agonists specifically for treating obesity.
Why does the combination help? In plain terms, the receptors don't just add up — they complement each other. GLP-1 curbs appetite and helps insulin; GIP and glucagon tune energy use and how the body handles sugar and fat. Engineered together, a single molecule can do what used to take a combination of drugs.
So when you read about a powerful new weight or diabetes drug, the short version is that it is probably not mimicking one hormone — it is a multi-receptor agonist, and the 2022 patent record is where that whole generation was being staked out.